Skip to content

Bio-Techne Corporation to Acquire Asuragen

Vinson & Elkins advised Asuragen, Inc., a medical technology company and a leader in the development, manufacturing and commercialization of genetic carrier screening and oncology testing kits, in an agreement to be acquired by Bio-Techne Corporation, a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, for initial consideration of $215 million in cash plus contingent consideration of up to $105 million upon the achievement of certain future milestones.

The V&E corporate team was led by partner Milam Newby and senior associate Michael Gibson, with assistance from senior associate Yong Eoh and associates Kelly King and Christina Wu. Also advising were partner Shane Tucker and senior associate Austin Light; partner Devika Kornbacher and senior associate Ben Cukerbaum; partner Lina Dimachkieh, senior associate Allyson Seger and associate Jeff Slusher; partner Hill Wellford, senior associate Ryan Will and associate Molly McDonald; senior associate Alex Bluebond; counsel Hal Taylor; counsel Larry Pechacek and senior associate Rachel Comeskey; counsel Elizabeth McIntyre; and counsel Sarah Mitchell.

About Vinson & Elkins
For more than 100 years, Vinson & Elkins has provided deep experience in handling transactions, investments, projects, and disputes worldwide. The firm is a trusted adviser to clients in the most important industrial and digital industries. Learn more by visiting www.velaw.com or follow us on Twitter @VinsonandElkins or connect with us on LinkedIn.

For more information, please speak with our media contacts.